Otsuka Pharmaceutical’s subsidiary has announced interim analysis results of the Phase 3 trial for the IgA nephropathy treatment drug cebepraelimab, demonstrating renal function preservation and progressing with approval application to the US FDA. There are no changes to the consolidated performance forecast for the fiscal year ending December 2026.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4578","jir_company_name":"Otsuka Holdings Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-06-05","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/06\/4578-20260605-01.pdf","jir_short_summary":"Otsuka Pharmaceutical's subsidiary has announced interim analysis results of the Phase 3 trial for the IgA nephropathy treatment drug cebepraelimab, demonstrating renal function preservation and progressing with approval application to the US FDA. There are no changes to the consolidated performance forecast for the fiscal year ending December 2026.","jir_summary":"### Performance Overview\nOtsuka Pharmaceutical's subsidiary announced interim analysis results of the Phase 3 trial for the IgA nephropathy treatment drug cebepraelimab. The trial successfully maintained eGFR over 12 months, demonstrating therapeutic effect. Subsequently, renewal applications are being progressively submitted to the US FDA. The results suggest potential for renal function decline suppression, raising expectations for long-term prognosis improvement. There are no changes to the consolidated performance forecast for the fiscal year ending December 2026.\n\n### Future Outlook and Investor Impact\nIn response to favorable interim analysis results, preparations are underway for formal approval of cebepraelimab. Acquisition of long-term clinical data and approval in the US market are expected to enable revenue generation and business expansion for this treatment. Safety profiles are also favorable, and the final results of future clinical trials are anticipated to further contribute to long-term prognosis improvements.","jir_financial_highlights":"eGFR change (12 months): +0.7 mL\/min\/1.73 m\u00b2 (Showing treatment effect compared to the placebo group at \u22124.8 mL\/min\/1.73 m\u00b2)\nTreatment Effect Difference: 5.5 mL\/min\/1.73 m\u00b2 (Difference in average eGFR change at 12 months)\neGFR slope (annual change rate): \u22123.0 mL\/min\/1.73 m\u00b2\/year (Improvement compared to the placebo group at \u22127.6 mL\/min\/1.73 m\u00b2\/year)","jir_category":"","jir_hashtags":"#OtsukaHoldings, #IR, #JapaneseStocks","jir_key_figures":"eGFR change (12 months): +0.7 mL\/min\/1.73 m\u00b2\nTreatment Effect Difference: 5.5 mL\/min\/1.73 m\u00b2\neGFR slope (annual change rate): \u22123.0 mL\/min\/1.73 m\u00b2\/year","jir_meta_title":"[Otsuka Holdings] Favorable Phase 3 Trial Results of IgA Nephropathy Drug | June 2026","jir_meta_description":"Otsuka Pharmaceutical's subsidiary announced interim analysis results of the Phase 3 trial for the IgA nephropathy treatment drug cebepraelimab. Demonstrated renal function maintenance, progressing with US approval application. No change to the earnings forecast for the fiscal year ending December 2026.","jir_og_title":"[Otsuka Holdings] Favorable IgA Nephropathy Drug Trial | June 2026","jir_og_description":"Otsuka Pharmaceutical subsidiary's IgA nephropathy treatment drug cebepraelimab showed maintained renal function in Phase 3 interim analysis and is progressing with approval application. The FY2026 forecast remains as expected.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":6875,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-61418","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n